Author

J. Copeland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Andalibi· 1 shared A. Luchini· 1 shared A. Mitra· 1 shared A. Narayanan· 1 shared A. Pak· 1 shared A. R. Reddi· 1 shared B. Hetrick· 1 shared D. Dabbagh· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Andalibi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The terminal heme synthetic enzyme, Coproheme Decarboxylase, coordinates heme synthesis and uptake in response to iron in Mycobacteria

R. K. Donegan, J. Copeland, S. Edgha, G. Brown, O. F. Hale, A. Mitra, H. Yang, H. A. Dailey, M. Niederweis, P. Jain, A. R. Reddi

This study identifies Coproheme Decarboxylase (ChdC) as a regulator of heme synthesis and uptake in Mycobacterium tuberculosis, showing it controls heme bioavailability and iron acquisition in response to iron availability.

bioRxiv · May 10, 2021 · PreprintMicrobiology

Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs

B. Hetrick, S. He, L. D. Chilin, D. Dabbagh, F. Alem, A. Narayanan, A. Luchini, T. Li, X. Liu, J. Copeland, A. Pak, T. Cunningham, L. Liotta, E. Petricoin, A. Andalibi, Y. Wu

This paper develops a hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening of neutralizing antibodies, viral variants, and antiviral drugs, showing increased infectivity of variants and enhanced neutralization by post-vaccination serum.

bioRxiv · Dec 22, 2020 · PreprintMicrobiology